AI Article Synopsis
- Female BALB/c mice treated with phenobarbitone or beta-naphthoflavone showed increased levels of liver enzymes that help metabolize xenobiotics and enhanced conversion of the carcinogen MeIQx to a more harmful form.
- Specifically, phenobarbitone was the only treatment that boosted the liver's ability to activate aflatoxin B1 in lab tests.
- However, both treatments reduced the overall in vivo mutagenic activity of aflatoxin B1 and MeIQx, suggesting the potential for the host-mediated assay to predict cancer risks related to liver enzyme induction.
Article Abstract
Intraperitoneal treatment of female BALB/c mice with either phenobarbitone or beta-naphthoflavone led to the induction of various hepatic enzymes associated with xenobiotic metabolism and to increased abilities of hepatic S9 fractions to convert the dietary carcinogen 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) to an active bacterial mutagen. In the case of another carcinogen, aflatoxin B1 an increase in in vitro hepatic activation was seen only in mice treated with phenobarbitone. In contrast, pretreatment with either phenobarbitone or beta-naphthoflavone reduced the in vivo activity of both aflatoxin B1 and MeIQx in the host mediated bacterial mutation assay. These data indicate that, for some carcinogens at least, the host-mediated assay may be used to predict the carcinogenic consequences of hepatic enzyme induction.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0027-5107(92)90236-u | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!